Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex.
about
Gene expression patterns in ovarian carcinomasMetal- and Semimetal-Containing Inhibitors of Thioredoxin Reductase as Anticancer AgentsCrystal structure and catalysis of the selenoprotein thioredoxin reductase 1Comparative analysis of glutaredoxin domains from bacterial opportunistic pathogensTrxR1 as a potent regulator of the Nrf2-Keap1 response systemReview of Cisplatin and oxaliplatin in current immunogenic and monoclonal antibody treatmentsReengineering redox sensitive GFP to measure mycothiol redox potential of Mycobacterium tuberculosis during infectionRapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteineTargeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.Cell death by SecTRAPs: thioredoxin reductase as a prooxidant killer of cellsMetformin induces an intracellular reductive state that protects oesophageal squamous cell carcinoma cells against cisplatin but not copper-bis(thiosemicarbazones).Cisplatin and oxaliplatin are toxic to cochlear outer hair cells and both target thioredoxin reductase in organ of Corti culturesThe anticancer agent chaetocin is a competitive substrate and inhibitor of thioredoxin reductase.Inhibition of thioredoxin reductase 1 by porphyrins and other small molecules identified by a high-throughput screening assayThe selenium-independent inherent pro-oxidant NADPH oxidase activity of mammalian thioredoxin reductase and its selenium-dependent direct peroxidase activities.S-glutathionylated serine proteinase inhibitors as plasma biomarkers in assessing response to redox-modulating drugsEvaluation of a dithiocarbamate derivative as an inhibitor of human glutaredoxin-1.Enhancement of carboplatin-mediated lung cancer cell killing by simultaneous disruption of glutathione and thioredoxin metabolism.Susceptibility of the antioxidant selenoenyzmes thioredoxin reductase and glutathione peroxidase to alkylation-mediated inhibition by anticancer acylfulvenesMolecular mechanisms of resistance and toxicity associated with platinating agents.Auranofin is a potent suppressor of osteosarcoma metastasis.Comparison of N-acetylmethionine reactivity between oxaliplatin and an oxaliplatin derivative with chiral (S,S) amine nitrogen atoms.Redox activation of Fe(III)-thiosemicarbazones and Fe(III)-bleomycin by thioredoxin reductase: specificity of enzymatic redox centers and analysis of reactive species formation by ESR spin trappingGlucose deprivation-induced metabolic oxidative stress and cancer therapy.Targeting selenium metabolism and selenoproteins: novel avenues for drug discoveryAnticancer activity of metal complexes: involvement of redox processes.Pt-based drugs: the spotlight will be on proteins.Thioredoxin reductase and its inhibitors.Biomarkers to assess the efficiency of treatment with platinum-based drugs: what can metallomics add?Ncf1 polymorphism reveals oxidative regulation of autoimmune chronic inflammation.Physical interaction between human ribonucleotide reductase large subunit and thioredoxin increases colorectal cancer malignancy.Comparative analyses of cytotoxicity and molecular mechanisms between platinum metallointercalators and cisplatin.Thioredoxin reductase 1 knockdown enhances selenazolidine cytotoxicity in human lung cancer cells via mitochondrial dysfunctionSelenoprotein P protects endothelial cells from oxidative damage by stimulation of glutathione peroxidase expression and activity.Interactions of nitroaromatic compounds with the mammalian selenoprotein thioredoxin reductase and the relation to induction of apoptosis in human cancer cells.N',N'-Dimethyl-N',N'-bis(phenylcarbonothioyl) Propanedihydrazide (Elesclomol) Selectively Kills Cisplatin Resistant Lung Cancer Cells through Reactive Oxygen Species (ROS).The mode of cisplatin-induced cell death in CYP2E1-overexpressing HepG2 cells: modulation by ERK, ROS, glutathione, and thioredoxin.2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cellsStimulation of human TRPA1 channels by clinical concentrations of the antirheumatic drug auranofin.Review of Cisplatin and Oxaliplatin in Current Immunogenic and Monoclonal Antibodies Perspective.
P2860
Q24644996-CA5FC5E5-5AA4-40DE-A1A6-B5D8BE5C83AFQ26800031-4B64AC9A-4F2F-40A3-8A68-C724F268FF85Q27653053-D9637B8A-5578-485C-9172-012D9B792608Q27673632-A8046C28-9A59-483A-B790-AD12BE9E9DF6Q28080723-C548756C-475A-4CED-89BA-AB306488E040Q28082382-0D4921A5-E696-4073-B318-E38C1A6B41DDQ28539327-C1559C7C-C8B8-4EB9-9E73-76DD629D85E6Q28571098-AD0918D2-0FAE-4C53-BAC8-2ED61AF92770Q33291299-AA6765AF-19FB-411F-A441-A93FFC72B906Q33326607-18E84B9F-4118-428B-B4FC-956EB606118DQ33610569-35B40343-4619-4A6C-A0E9-30ABA83C3639Q33630058-6986A5AE-4BBB-45E0-9FC5-EF7522EFA36AQ33741157-86C4CA3E-294D-4BF9-81ED-499CFE008FD7Q33801828-E324B2FC-6302-496B-B7B6-E8746F10E88CQ33967269-A616217F-4B86-434C-AEA4-30E41195531EQ34117297-ADF5B44E-EB2E-4104-8D81-7625C5EA081EQ35027523-EBE36647-92C6-4E70-BA42-B794416D93ECQ35269285-CB9BEC74-3AD2-4DF4-88CC-18021E08FB86Q35535940-421500DB-99DB-422F-8D39-0326224ACCE6Q35758048-BB33CBBD-7710-4DCE-9FF5-3AE114A47F3CQ36729542-8EBFB109-9FC5-421A-86CD-8BDDA8B7B5D9Q36792043-959AD210-3329-4D42-8C2F-525457EF165AQ36844094-ECBC3CA2-5543-4D72-9E5B-7D25ABC5D02FQ37653791-227E5FF3-719F-4A1F-B83C-C8484EF8DABDQ37808628-F6C94D2B-F859-4E13-BEA0-45F7451037B1Q37833099-657D0F7A-7886-495B-8496-3E5EA607B931Q38186602-8D77EA7A-5616-46CB-9D4C-B9C70697980CQ38215943-FC43B013-B8C0-4E68-BF18-EF61A6E98235Q38267182-36BDDEE5-C84F-40C5-BBE2-76E1C08EB612Q38673434-862CBC47-EDC5-46C4-B47F-99A8FC926724Q38707613-192E8273-E864-4178-AEDC-D5EF0BD4E196Q39311584-C72C348E-635E-492D-A915-99EE34C77F92Q39648281-3AA1D150-D066-4B87-9CA0-EDBE6BAB8B59Q40224951-7B3BAF30-45BE-4CC0-A34C-88D0C4C7051AQ40340040-A83A4412-56C2-49C9-B58F-04296BF1E68FQ40927454-946ED3DB-EEC0-4C80-8CCA-FF49DCF7612DQ41311155-77F99848-A6EE-46ED-B247-CDD87533CA40Q42114282-BF57A37C-6F3B-4044-9E0C-E8FEC199030FQ42713895-F1C1904E-B9BC-4FCD-9918-5A65AC1C0109Q44242635-EEA3B270-28C7-407B-8C14-1D7FBA9CD7CB
P2860
Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Analysis of the inhibition of ...... glutathione-platinum complex.
@en
Analysis of the inhibition of ...... glutathione-platinum complex.
@nl
type
label
Analysis of the inhibition of ...... glutathione-platinum complex.
@en
Analysis of the inhibition of ...... glutathione-platinum complex.
@nl
prefLabel
Analysis of the inhibition of ...... glutathione-platinum complex.
@en
Analysis of the inhibition of ...... glutathione-platinum complex.
@nl
P2093
P1476
Analysis of the inhibition of ...... glutathione-platinum complex.
@en
P2093
P304
P356
10.1016/S0891-5849(01)00698-0
P577
2001-11-01T00:00:00Z